August 16, 2023
Discovery of KT-474, a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases
American Chemical Society (ACS) Fall 2023 Meeting
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
July 24, 2023
Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders
Gadiyar, V., Patel, G., Chen, J., Vigil, D., Ji, N., Campbell, V., Sharma, K., Shi, Y., Weiss, M., Birge, R., & Davra, V.
Read More
June 14, 2023
Phase 1 trial of KT-333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors
International Conference on Malignant Lymphoma (ICML) 2023
CTCL
LGL-L
PTCL
Solid Tumors
Read More
June 6, 2023
Pulse Dosing of Potent and Selective Heterobifunctional MDM2 Degrader KT-253 Drives Tumor Regression and Demonstrates Differentiated Pharmacology Compared to p53/MDM2 Small Molecule Inhibitors
European Hematology Association (EHA) 2023 Hybrid Congress
Liquid Tumors
Read More
May 18, 2023
Safety and Efficacy of IRAK4 Degrater KT-474 (SAR444656) for Hidradenitis Suppurativa and Atopic Dermatitis
European Academy of Dermatology & Venereology (EADV) Symposium 2023
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
December 12, 2022
Precision Targeting of MYD88 Mutant DLBCL Using the Novel Combination of IRAKIMiD sand BCL2 Inhibition
American Society of Hematology Annual Meeting and Expo
MYD88 Tumors
Read More
December 12, 2022
Leveraging Pre-Clinical Animal Model of CTCL to Explore Therapeutic Potential of a Novel STAT3 Degrader
American Society of Hematology Annual Meeting and Expo
CTCL
Read More
December 11, 2022
Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the treatment of Acute Myeloid Leukemia
American Society of Hematology Annual Meeting
Liquid Tumors
Read More
December 7, 2022
Proteomics enabling TPD Drug Discovery
TPD Assay Development and Screening Summit
Read More
October 27, 2022
Discovery of a First-In-Class MDM2 Degrader for the Treatment of Relapsed/Refractory TP-53 Wt AML & Solid Tumors
5th Annual Targeted Protein Degradation (TPD) Summit
Liquid Tumors
Solid Tumors
Read More